Please login to the form below

OPEN Health mobilised to support outcomes with gene and other advanced therapies

Harnessing the power of collaborations to bring real insights and improve outcomes

The imminent explosion of gene and other advanced therapies brings with it a lot of hope and expectation along with unprecedented challenges faced by bio-pharma - big and small.

The power of the rare disease community has to be harnessed to get these potentially life changing treatments into health systems and to patients in a timely and sustainable fashion.

These are rapidly evolving and exciting times where everyone is learning together and collaboration is key to ensure best practice and novel approaches see widespread adoption.

OPEN Health brought together our existing knowledge in the space to develop experience based thinking on the topics of creating insight and value for gene and other advanced therapies. In addition OPEN Health always values opinion leaders in a particular field and were therefore delighted to be able to interview Nicki Redfern from bluebird bio to hear about their progress and the evolving landscape.

Finally we focus on what we see as a key challenge that requires a new approach. This is how do you deliver effective and sustained outcomes monitoring following initiation of one of these innovative therapies. Read our thinking in this space here.

Pink divider

Get in touch

For more information contact Gavin Jones | Director of Rare Disease | OPEN Health
GavinJones@OpenHealthGroup.com

+44 (0) 7795 038952

30th October 2019

Share

Company Details

OPEN Health

+44 1628 481112

Contact Website

Address:
The Weighbridge
Brewery Courtyard
High Street
Marlow
Buckinghamshire
SL7 2FF
United Kingdom

Latest content on this profile

OPEN Health Appoints David P. King as Non-Executive Chairman and Paul Carter as Independent Board Member
OPEN Health has announced additions to its board of directors, appointing David P. King as non-executive Chairman and Paul Carter as an independent board member.
OPEN Health
Steve Chick joins OPEN Health as Chief Growth Officer for Evidence & Access
OPEN Health is pleased to announce the appointment of Stephen J. Chick as Chief Growth Officer for OPEN Health Evidence & Access.
OPEN Health
OPEN Health to acquire leading US medical communications platform The CM Group from NaviMed Capital
OPEN Health, a pre-eminent global provider of scientific communications and market access services, announced that it signed a binding agreement to acquire The CM Group, a leading US domestic medical communications platform from NaviMed Capital (“NaviMed”).
OPEN Health
How digital health is changing the relationship between patients and health providers | OPEN Health
The pandemic has forced pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes
OPEN Health
David Thompson joins OPEN Health as Chief Executive Officer for Evidence & Access
David Thompson joins OPEN Health as Chief Executive Officer for Evidence & Access
OPEN Health
OPEN Health Appoints Chief Medical Officer Annemarie Clegg, MD, and Chief Commercial Officer Jennifer Chilver
OPEN Health Appoints Chief Medical Officer Annemarie Clegg, MD, and Chief Commercial Officer Jennifer Chilver
OPEN Health